MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, announced the appointment of Salomon (Sam) Azoulay, M.D, as Chief Medical Officer (CMO). Dr. Azoulay is an accomplished physician-scientist with over 35 years of experience in drug development and… Continue reading MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer